After years of waiting, in which your business came ever closer to the “patent cliff,” the FDA has released its long-awaited user fee structure and draft guidelines for the development and regulatory approval of biosimilars in the United States.
The 13th Annual Business of Biosimilars and Generic Drugs event is designed to help you focus on the most significant new points in these guidelines and further accelerate what indeed promises to be a significantly abbreviated path to approval for your follow-on biologics.
No other event focuses so sharply on eliminating the obstacles you face in the commercialization of your next biosimilar candidate. This year we are particularly proud to feature time-sensitive updates on the biggest news now facing the industry!
What is featured in this year’s Business of Biosimilars and Generic Drugs event?
- FDA REGULATORY UPDATES
- STRATEGIC PARTNERSHIPS
- LEARNING THE RIGHT MARKET LESSONS FROM GENERIC DRUGS
For the complete program, download the 2012 agenda.
13th Annual Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. As a reader of The Drug Delivery Blog, you receive an exclusive discount of 25% off of the standard rate when you register to join us. Simply use priority code XP1786BLOG. Have any questions about the event? Feel free to email Jennifer Pereira.